This list contains only the countries for which job offers have been published in the selected language (e.g., in the French version, only job offers written in French are displayed, and in the English version, only those in English).
Beam is seeking a driven and scientifically rigorous Director of Medical Information to build and lead the Medical Information (MI) function. This is a hands-on leadership role well-suited to a motivated individual contributor and emerging leader who is passionate about establishing strong operational foundations and delivering high-quality scientific content in the rare disease space. The Director of Medical Information will design and implement core MI capabilities — including inquiry management systems, standard response documents, and medical review workflows — positioning the organization for its first commercial launch and scaling for future clinical programs. The Director of Medical Information will also play an active role in the company's Medical Affairs AI initiatives, contributing scientific and operational expertise to the responsible deployment of AI-enabled tools for content generation and knowledge management.
Job Responsibility:
Establish the Medical Information department from the ground up, including defining the operating model, staffing plan, technology infrastructure, and standard operating procedures (SOPs)
Develop and maintain the MI quality framework to ensure all scientific content meets regulatory, compliance, and scientific integrity standards
Serve as the internal subject matter expert on medical information best practices, regulatory expectations (FDA, EMA), and industry benchmarks for rare disease and advanced therapies
Build and oversee the medical review process for promotional and non-promotional materials, ensuring scientific accuracy and alignment with label and clinical data
Partner in the establishment of a Medical Review Committee (MRC) / Promotional Review Committee (PRC), collaborating closely with Regulatory Affairs, Legal, and Commercial teams
Create and maintain a comprehensive library of standard response documents (SRDs), custom responses, and medical FAQs covering the company's cell and gene therapy pipeline across rare disease indications
Author and review medical information letters, disease education materials, clinical summaries, and scientific dossiers for internal and external use
Ensure all MI content reflects the most current evidence base, including clinical trial data, real-world evidence, and peer-reviewed literature
Partner with Medical Science Liaisons (MSLs), Clinical Development, and Commercial teams to develop scientifically rigorous training materials, slide decks, and internal reference tools
Lead the development of pipeline and disease area resources that enable cross-functional teams to communicate accurately about the science of cell and gene therapies
Contribute to publication planning and medical education initiatives, supporting the Medical Affairs strategy for pre-launch and post-launch activities
Collaborate with Patient Advocacy and Medical Communications to ensure content is accessible, accurate, and patient-centered
Contribute as a Medical Affairs subject matter expert to the company's AI strategy, partnering with Data Science, IT, and Medical Affairs leadership to evaluate and implement AI-enabled solutions
Support the design and validation of AI-assisted medical information tools, including intelligent response generation, literature surveillance automation, and content quality-checking workflows
Participate in establishing governance frameworks for responsible AI use in medical communications, including bias assessment, hallucination mitigation, and compliance review protocols
Monitor the evolving regulatory and industry landscape around AI in medical affairs (e.g., FDA guidance, ISPE, PhRMA frameworks) and translate insights into actionable policies
Requirements:
Advanced scientific degree required: PharmD, MD, PhD, or equivalent in life sciences, pharmacy, or a related field
Minimum 7 years of experience in Medical Information, Medical Affairs, or Medical Communications within the pharmaceutical or biotechnology industry
Experience contributing to or building Medical Information capabilities, including SOP development and content library management
Solid working knowledge of medical review processes (MRC/PRC) and promotional/non-promotional content review, with familiarity with applicable FDA and EMA regulations
Strong scientific writing skills with experience developing SRDs, medical information responses, and clinical content for internal and external audiences
Ability to work effectively cross-functionally in a fast-paced, pre-commercial biotech environment with lean teams and evolving priorities
Interest in or exposure to rare disease therapeutic areas, including the scientific and operational challenges of small patient populations
Experience in cell and gene therapy, gene editing, or other advanced therapy medicinal products, preferred
Exposure to AI/ML applications in Medical Affairs or Medical Information, including prompt engineering, LLM evaluation, or AI governance, preferred
Familiarity with medical information platforms (e.g., Veeva Vault, Salesforce Health Cloud, MedAnswers) or emerging AI-powered MI solutions, preferred
Experience supporting pre-BLA/pre-NDA activities or commercial launch readiness for orphan-designated or first-in-class therapies, preferred
Onsite requirements: Must be able to work onsite as required and willing to have a flexible schedule during peak times, which may include supporting critical operations outside of normal work hours, as needed.
Nice to have:
Experience in cell and gene therapy, gene editing, or other advanced therapy medicinal products
Exposure to AI/ML applications in Medical Affairs or Medical Information, including prompt engineering, LLM evaluation, or AI governance
Familiarity with medical information platforms (e.g., Veeva Vault, Salesforce Health Cloud, MedAnswers) or emerging AI-powered MI solutions
Experience supporting pre-BLA/pre-NDA activities or commercial launch readiness for orphan-designated or first-in-class therapies